Silibinin, the main compound in milk thistle, is studied as a low-cost add-on to standard cancer care, not a replacement. Early human signals are modest improvements in prostate cancer markers and some activity against cancer spread to the brain. Evidence stays preliminary, absorption is poor, and safety is reassuring with mild digestive effects. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT / AST | ~10–26 U/L each | Track liver safety and hepatoprotective effect |
| PSA | Track trend; functional target <1.0 ng/mL in non-cancer context | Primary response marker in prostate cancer |
| IGF-1 | Mid-to-lower age-adjusted reference range | Growth-promoting hormone silibinin lowers in prostate cancer |
| Complete blood count | Within normal range | Baseline safety and chemotherapy-context monitoring |
| INR (if on warfarin) | Per anticoagulation target (often 2.0–3.0) | Detect additive bleeding-risk interaction |
| hs-CRP | <1.0 mg/L | Track anti-inflammatory effect relevant to silibinin's proposed action |
Cadence: Prostate cancer: PSA and IGF-1 every 4–12 weeks; liver enzymes at baseline, ~4 weeks, then every 3–6 months. Narrow-index co-meds (e.g., INR) per that drug's schedule. Brain-metastasis imaging typically every 2–3 months.